Using an in-house developed monoclonal antibody to RASSF1A, we observed robust staining of descending colon sections from non-IBD patients, but reduced or no staining in UC or CD patients (Figure 1B), whereby the RASSF1A positive staining is reduced by >50% in most IBD patients (Figure 1B). Here, RASSF1 is linked to irritable bowel syndrome.